This article was originally published in The Gray Sheet
Cardiac electrophysiology products company's $3.25 mil. equity financing agreement is led by Cardiac Capital, which is 50% owned by EP MedSystems Chairman and CEO David Jenkins. Cardiac Capital will receive 1.5 mil. shares of common stock and warrants for 750,000 additional shares exercisable at $4, out of a total 1.63 mil. shares and 812,500 warrants. Jenkins has agreed not to sell any previously owned shares for one year after the deal closes. Proceeds will be used to expand the Mt. Arlington, New Jersey firm's sales, marketing and manufacturing capabilities. FDA has granted EP MedSystems' ALERT catheter expedited PMA review for treatment of atrial fibrillation
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.
Alvogen believes it is the first company to file for a generic pazopanib rival to Novartis’ Votrient oncology brand in Europe.